T2	Disorder 56 77	methotrexate toxicity
N1 	Reference T2 UMLS:C0568062	methotrexate toxicity
T3	Pharmacological_substance 80 92	Methotrexate
N1000 	Reference T3 MeSH:D008727	Methotrexate
T4	Disorder 145 154	psoriasis
N2 	Reference T4 UMLS:C0033860	psoriasis
T6	Disorder 176 197	methotrexate toxicity
N3 	Reference T6 UMLS:C0568062	methotrexate toxicity
T7	Disorder 206 229	bone marrow suppression
N4 	Reference T7 UMLS:C0854467	bone marrow suppression
T9	Disorder 334 355	methotrexate toxicity
N5 	Reference T9 UMLS:C0568062	methotrexate toxicity
T10	Disorder 385 408	bone marrow suppression
N6 	Reference T10 UMLS:C0854467	bone marrow suppression
T11	Disorder 469 478	psoriasis
N7 	Reference T11 UMLS:C0033860	psoriasis
T13	Disorder 528 536	toxicity
N8 	Reference T13 UMLS:C0600688	toxicity
T14	Subject 422 434	two patients
T16	Speculation_cue 113 124	potentially
T18	Disorder 243 270	gastrointestinal ulceration
N9 	Reference T18 UMLS:C0237938	gastrointestinal ulceration
T19	Disorder 234 238;260 270	oral ulceration
N10 	Reference T19 UMLS:C0149745	oral ulceration
T21	Disorder 9 37	Erosion of psoriatic plaques
T23	Disorder 272 308	Painful erosion of psoriatic plaques
T25	Disorder 443 459	painful erosions
T5	Pharmacological_substance 515 527	methotrexate
N1001 	Reference T5 MeSH:D008727	methotrexate
